Characteristics of patients with T315I mutation, other mutations, and no mutations
| Characteristics . | No mutation . | Mutation group . | P . | |
|---|---|---|---|---|
| T315I . | Other mutation . | |||
| Patients, no. (%) | 82 (44) | 27 (15) | 77 (41) | |
| Age, y (range) | 49 (11-96) | 52 (25-60) | 52 (17-80) | .489 |
| Female sex, no. (%) | 44 (54) | 9 (33) | 31 (40) | .097 |
| Prior therapy with interferon alpha, no. (%) | 42 (51) | 13 (48) | 51 (66) | .097 |
| Median time from diagnosis to treatment with imatinib, mo (range) | 11 (1-293) | 4 (1-175) | 24 (1-165) | .017 |
| CML phase at the start of imatinib, no. (%) | ||||
| Chronic | 63 (77) | 21 (78) | 61 (79) | .911 |
| Accelerated | 13 (16) | 4 (15) | 13 (17) | |
| Blastic | 6 (7) | 2 (7) | 3 (4) | |
| Best response to imatinib, no. (%) | ||||
| CHR | 35 (43) | 19 (70) | 39 (51) | .454 |
| MCyR | 34 (41) | 7 (26) | 31 (40) | |
| CCyR | 25 (30) | 5 (19) | 21 (27) | |
| Response duration, mo (range) | 45 (2-69) | 44 (1-60) | 49 (2-70) | .793 |
| CML phase at imatinib failure, no. (%) | ||||
| Chronic | 28 (34) | 10 (37) | 28 (36) | .575 |
| Accelerated | 30 (37) | 9 (33) | 35 (45) | |
| Blastic | 24 (29) | 8 (30) | 14 (18) | |
| Transformation to accelerated–blastic phase, no. (%) | 42 (51) | 15 (56) | 41 (53) | .919 |
| No. treated with second TKI | 76 | 14 | 75 | |
| Response to second TKI, no. (%) | ||||
| Hematologic | 64 (84) | 5 (36) | 61 (81) | .002 |
| Cytogenetic | 33 (43) | 0 (0) | 35 (47) | |
| No. dead (%) | 32 (39) | 11 (41) | 29 (38) | .958 |
| Median follow-up after imatinib failure, mo (range) | 24 (2-68) | 29 (4-55) | 29 (4-73) | .368 |
| Median time on imatinib, mo (range) | 28 (2-70) | 47 (2-60) | 35 (2-71) | .244 |
| Characteristics . | No mutation . | Mutation group . | P . | |
|---|---|---|---|---|
| T315I . | Other mutation . | |||
| Patients, no. (%) | 82 (44) | 27 (15) | 77 (41) | |
| Age, y (range) | 49 (11-96) | 52 (25-60) | 52 (17-80) | .489 |
| Female sex, no. (%) | 44 (54) | 9 (33) | 31 (40) | .097 |
| Prior therapy with interferon alpha, no. (%) | 42 (51) | 13 (48) | 51 (66) | .097 |
| Median time from diagnosis to treatment with imatinib, mo (range) | 11 (1-293) | 4 (1-175) | 24 (1-165) | .017 |
| CML phase at the start of imatinib, no. (%) | ||||
| Chronic | 63 (77) | 21 (78) | 61 (79) | .911 |
| Accelerated | 13 (16) | 4 (15) | 13 (17) | |
| Blastic | 6 (7) | 2 (7) | 3 (4) | |
| Best response to imatinib, no. (%) | ||||
| CHR | 35 (43) | 19 (70) | 39 (51) | .454 |
| MCyR | 34 (41) | 7 (26) | 31 (40) | |
| CCyR | 25 (30) | 5 (19) | 21 (27) | |
| Response duration, mo (range) | 45 (2-69) | 44 (1-60) | 49 (2-70) | .793 |
| CML phase at imatinib failure, no. (%) | ||||
| Chronic | 28 (34) | 10 (37) | 28 (36) | .575 |
| Accelerated | 30 (37) | 9 (33) | 35 (45) | |
| Blastic | 24 (29) | 8 (30) | 14 (18) | |
| Transformation to accelerated–blastic phase, no. (%) | 42 (51) | 15 (56) | 41 (53) | .919 |
| No. treated with second TKI | 76 | 14 | 75 | |
| Response to second TKI, no. (%) | ||||
| Hematologic | 64 (84) | 5 (36) | 61 (81) | .002 |
| Cytogenetic | 33 (43) | 0 (0) | 35 (47) | |
| No. dead (%) | 32 (39) | 11 (41) | 29 (38) | .958 |
| Median follow-up after imatinib failure, mo (range) | 24 (2-68) | 29 (4-55) | 29 (4-73) | .368 |
| Median time on imatinib, mo (range) | 28 (2-70) | 47 (2-60) | 35 (2-71) | .244 |
CP indicates chronic phase; AP, accelerated phase; BP, blastic phase; CHR, complete hematologic response; MCyR, major cytogenetic response; and CCyR, complete cytogenetic response.